BCL2, BCL2 apoptosis regulator, 596

N. diseases: 1456; N. variants: 27
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 AlteredExpression group BEFREE Patients with abdominal nodal disease had inferior lymphoma specific survival (p=0.04) and presented with higher age adjusted IPI (p<0.001), lactate dehydrogenase (p<0.001) and more often advanced stage (p<0.001), bulky disease (p<0.001), B-symptoms (p<0.001), and double expression of MYC and BCL2 (p=0.02) compared to patients without nodal abdominal involvement, but less often extranodal involvement (p<0.02). 31785002 2020
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE New targeted therapies for hematological malignancy include chimeric antigen receptor T cells (CAR T cells), Bi-specific T-cell Engager (BiTE) blinatumomab, and the antibody-drug conjugate (ADC) of calicheamicin inotuzumab ozogamicin for acute lymphoblasic leukemia (ALL) and lymphoma; the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib and phosphatidylinositol 3-kinase (PI3Kδ) inhibitor idelalisib for lymphoma and graft-versus-host disease (GVHD); FMS-like tyrosine kinase 3 (FLT3) inhibitors, such as midostaurin, sorafenib and gilteritinib for acute myeloid leukemia (AML); and the BCL-2 inhibitor venetoclax for a range of hematological malignancies including lymphoma and leukemia. 31688198 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 GeneticVariation group BEFREE Aggressive lymphomas with MYC and BCL2 and/or BCL6 translocations ("double hit" lymphomas, DHL) represent a distinct diagnostic category in the updated World Health Organization (WHO) classification. 29629947 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE Both germinal center B cell (GCB) and double-expressor (MYC+/Bcl2+) lymphomas were found in 21%. 31189479 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 AlteredExpression group BEFREE Notably, Rac1 expression, and its interaction with Bcl-2, positively correlate with S70pBcl-2 levels in patient-derived lymphoma tissues and with advanced stage lymphoma and melanoma. 31103719 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE The expression levels of MMP-9 and Bcl-2 were correlated with the body weight loss degree of mice, and the expression of MMP-9 was positively associated with that of BCL-2 in lymphomas. 30779087 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE Abbreviations: APC/C: Anaphase-Promoting Complex/Cyclosome; BAD: BCL2-Associated agonist of cell Death; BAK1: BCL2 Antagonist Kinase1; BAX: BCL2-Associated X; BCL2: B-cell Chronic Lymphocytic Leukaemia (CLL)/Lymphoma 2; BH: BCL2 Homology Domain; BID: BH3-Interacting domain Death agonist; BIM: BCL2-Interacting Mediator of cell death; BUB: Budding Uninhibited by Benzimidazoles; CDC: Cell Division Cycle; CDH1: Cadherin-1; CDK1: Cyclin-Dependent Kinase 1; CEP55: Centrosomal Protein (55 KDa): CIN: Chromosomal Instability; CTA: Cancer Testis Antigen; EGR1: Early Growth Response protein 1; ERK: Extracellular Signal-Regulated Kinase; ESCRT: Endosomal Sorting Complexes Required for Transport; GIN: Genomic Instability; MAD2: Mitotic Arrest Deficient 2; MCL1: Myeloid Cell Leukemia sequence 1; MPS1: Monopolar Spindle 1 Kinase; MYT1: MYelin Transcription factor 1; PLK1: Polo Like Kinase 1; PUMA: p53-Upregulated Mediator of Apoptosis; SAC: Spindle Assembly Checkpoint; TAA: Tumor-Associated Antigen. 30601084 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 AlteredExpression group BEFREE However, no associations were found between DAPK methylation and clinicopathological features of lymphoma, in relation to gender (OR = 1.07, 95% CI (0.72, 1.59), P = 0.751), age (OR = 1.01, 95% CI (0.66, 1.55), P = 0.974), international prognostic index (OR = 1.20, 95% CI (0.63, 2.27), P = 0.575), B symptoms (OR = 0.76, 95% CI (0.38, 1.51), P = 0.452), serum lactate dehydrogenase (OR = 1.13, 95% CI (0.62, 2.05), P = 0.683), and BCL-2 expression (OR = 1.55, 95% CI (0.91, 2.66), P = 0.106). 30682070 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 AlteredExpression group BEFREE Amongst hematologic malignancies, these lymphomas are particular in that they express very low levels of B-cell lymphoma 2 (BCL2), a recognized inhibitor of apoptosis and autophagy, two processes that share complex interconnections. 30679328 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE Our analysis provided a novel look on the transition range between FL and DLBCL, on DLBCL with poor prognosis showing expression patterns resembling that of Burkitt's lymphoma and particularly on 'double-hit' MYC and BCL2 transformed lymphomas. 31039827 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE These results indicate that the survival of this type of lymphoma depends predominantly on BCL2 rather than on MCL1. 30523053 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 AlteredExpression group BEFREE Enhancer of zeste homolog 2 (EZH2) and Bcl-2 gene rearrangement or protein upregulation played pivotal roles in the carcinogenesis of various malignancies including lymphomas. 31205561 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 GeneticVariation group BEFREE High-grade B-cell lymphomas (HGBCL) with MYC and BCL2 or/and BCL6 rearrangements (R), so-called double/triple-hit lymphomas (DH/THL), are uncommon, clinically aggressive lymphomas that require a prompt diagnosis. 30734478 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE Thus, constitutive IP<sub>3</sub> signaling in lymphoma and leukemia cells is not only important for cancer cell survival, but also represents a vulnerability, rendering cancer cells dependent on Bcl-2 to limit IP<sub>3</sub>R activity. 29899382 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 GeneticVariation group BEFREE Double/triple-hit lymphomas (DHL/THL) account for 5-10% of diffuse large B cell lymphoma (DLBCL) with rearrangement of MYC and BCL2 and/or BCL6 resulting in MYC overexpression. 31288832 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 AlteredExpression group BEFREE We identified 122 patients diagnosed as having large B-cell lymphoma (44, MYC-negative; 29, MYC-EC; 23, MYC rearrangement; 22, MYC and BCL2 rearrangements; 4, MYC, BCL2, and BCL6 rearrangements). p53 expression significantly correlated with DLBCL with abnormal MYC status (MYC-EC, MYC rearrangement, and MYC overexpression), but adverse p53 prognostic effect was only seen with MYC-rearranged lymphoma. 30496802 2019
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 GeneticVariation group BEFREE When compared to two large published DTHL cohorts, t(3;8)(q27;q24) lymphomas less often expressed BCL2 (P < .01), had a greater likelihood of extranodal involvement (P < .01), and more frequently appeared triple-hit by FISH analysis (P < .01). 29902576 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE As bcl-2 proteins, cyclin dependent kinases (CDK) and phosphoinositol-3- kinase (PI3K) also influence mitochondrial physiology and metabolism with clear relevance to the pathogenesis of lymphoma, we investigated the potentiating effects of metformin when combined with novel agents Venetoclax (bcl-2 inhibitor), BAY-1143572 (CDK9 inhibitor) and Idelalisib (p110δ- PI3K inhibitor). 29765528 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 AlteredExpression group BEFREE Lymphomas with MYC and either BLC2 or BCL6 rearrangements or MYC and BCL-2 protein overexpression, classified as double-hit (DHL) or double-expressor (DEL) lymphomas, respectively, are associated with poorer response to standard immunochemotherapy. 29722657 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 AlteredExpression group BEFREE Stress signals trigger apoptosis via the pathway regulated by opposing fractions of the BCL-2 protein family and previous genetic studies have shown that the development of B lymphoid tumours in Eµ-Myc mice is critically dependent on expression of pro-survival BCL-2 relatives MCL-1, BCL-W and, to a lesser extent, BCL-X<sub>L</sub>, but not BCL-2 itself, and that sustained growth of these lymphomas is dependent on MCL-1. 29339775 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE Overexpression of the pro-survival member BCL-2 is a well-established mechanism contributing to oncogenesis and chemoresistance in several cancers, including lymphoma and leukemia. 29732004 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 AlteredExpression group BEFREE Optimal strategies have not been well defined for diagnosis of high grade B cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements (HGBLwR) and double expressor lymphomas with MYC and BCL2 protein overexpression. 28868942 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE Here we show that AICDA overexpression causes more aggressive disease in BCL2-driven murine lymphomas. 29335468 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE Mef2b<sup>D83V</sup> expression in mice leads to GC enlargement and lymphoma development, a phenotype that becomes fully penetrant in combination with BCL2 de-regulation, an event associated with human MEF2B mutations. 30205047 2018
CUI: C0024299
Disease: Lymphoma
Lymphoma
0.500 Biomarker group BEFREE MYC/BCL2/BCL6 triple hit lymphoma: a study of 40 patients with a comparison to MYC/BCL2 and MYC/BCL6 double hit lymphomas. 29785017 2018